April 15, 2020

IRT version 3.1.0 acquires some principal upgrades

(Moscow – 15.04.2020) InSysBio is one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling has published the new version of IRT database, one of its core products. IRT is strengthening its positions as an efficient and useful tool aimed to boost and facilitate the development of QSP models in immunology and immuno-oncology therapeutic areas. It was planned to present IRT version 3.1.0 in frames of international conferences, nevertheless it has already been made available.

Particularly, fundamental changes in IRT 3.1.0 include the addition of cytokines passports for more than 40 cytokines. Their full list can be found below.
Passports include equations describing cytokines synthesis by immune cells, cytokines distribution and degradation. Regulators impact on these processes is also implemented in the equations. Veronika Musatova, Head of IRT development team, highlights, “Together with cell passports included in IRT v.3.0.0, platform contains 910 equations, with more than 2700 parameters, 60% of them are directly taken, calculated from or fitted against available research data from open sources.”

Actually, great effort was made to maintain the database in its current shape. Moreover, IRT team is not going to lose their pace and is consistently focused on the future development. To fulfill all ever-evolving demands (with this aim) IRT team is gradually widening and getting new members. IRT future updates include:

• implementation of new cell passports: NK cells, Neutrophils, myeloid DC, plasmacytoid DC, Tc subpopulations;
• addition of new scheme type: cell production passport, describing cytokines synthesis by exact immune cell type;
• introduction of in vitro models and fitting information available in annotations;
• development of equations and full models export options.

Cytokines passports implemented in IRT v. 3.1.0: IL-1a, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12, IL-13, IL-17, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-31, IL-33, IFNa, IFNg, GM-CSF, TNFa, TGFb, Hn, TSLP, PGE2, IgE, NGF, VEGF, MCC, MCT, CCL2, CCL3, CCL4, CCL5, CCL11, CCL20, CXCL9, CCL17, CXCL10

For more information about IRT Version 3.1.0, please visit irt.insysbio.com.

About InSysBio:

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.

Share